drugset / Trial / NCT03643068
Phase 1A Study of the Safety of KSP/QRH Dimer
Non-randomizedParallel-groupOpen-labelOther
Summary
To evaluate the safety of orally administered KSP-QRH-E3-IRDye800 (Peptide 919288G), a topically administered Li-Cor IRDye800CW labeled heptapeptide dimer (KSP/QRH Dimer) specific for human epithelial growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR).
Timeline
- Start
- 2018-08-22
- Primary completion
- 2018-10-27
- Completion
- 2018-10-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KSP-QRH-E3-IRDye800 | Peptide | 0.6 mg | Oral |
| Subject | KSP-QRH-E3-IRDye800 | Peptide | 1.8 mg | Oral |
Indications
No indication recorded.